West Nile Virus
West Nile Virus (WNV), also known as West Nile Fever, is primarily a mosquito borne virus belonging the Flaviviridae family. In humans the majority of infections are subclinical with patients experiencing either no or very mild symptoms, however a minority of infections result in severe disease, which may result in fatal encephalitis.
Originating in Africa, WNV was, until recently, not a signifinant disease of humans. Since the the late 1990's the virus has spread widely to other continents and is now an endemic pathogen in the temperate and tropic reagions throughout the world. WNV infection is now considered a serious health concern in North America (Lindsey et al. 2014).
WNV is zoonotic disease with an avian wildlife resevoir to which passerine and more specifcally, corvid species appear to be particularly susceptible with high recorded mortality rates (Abdelrazec et al. 2014). In addition to the human health concerns and the effect on North American avian species populations (Wheeler et al. 2011), WNV is also of potential concern in domestic mammals, in particular to equine species where mortality rates are high (Agenvoort et al. 2013). Fatal cases of West Nile have also been noted other species including non-human primates, bats and cetaceans. While the primary route of infection is via mosquitos there is some evidence that infection may also occur from other invertebrate species such as ticks, however further research is required in this area.
Recombinant West Nile virus NS1 antigen is presented in its native folded state complete with post-translational modifications, delivering optimal antigenicity and making it suitable for use in vaccine research and serology-based assays.
- Target Species
- Product Form
- Purified recombinant protein - liquid
- Recombinant West Nile virus NS1 protein, sequence strain NY99, expressed in 293 human cells
- Buffer Solution
- Dulbecco's phosphate buffered saline
- Preservative Stabilisers
- None present
- >95% by SDS PAGE
- Approx. Protein Concentrations
- Approximate protein concentration 0.49 mg/ml
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch.
- For research purposes only
Applications of West Nile Virus
|Application Name||Verified||Min Dilution||Max Dilution|
Useful Reagents Available
|Description||Product Code||Applications||Pack Size||List Price||Quantity|
|Human anti WNV NS2B-NS3||HCA085||E WB||0.1 mg|
Product Specific References
Wheeler, S.S. et al. (2011) Efficacy of three vaccines in protecting Western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (Aphelocoma insularis).
Vector Borne Zoonotic Dis. 11(8): 1069–1080.
Abdelrazec, A, et al. (2014) Transmission dynamics of West Nile virus in mosquitoes and corvids and non-corvids.
J Math Biol. 68(6): 1553-82.
Lindsey, N.P. et al. (2014) West Nile Virus and Other Arboviral Diseases — United States, 2013.
MMWR Morb Mortal Wkly Rep. 63(24): 521-6.
Angenvoort, J. et al. (2013) West Nile viral infection of equids.
Vet Microbiol. 29: 167(1-2): 168-80.